Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, ...

Naturally occurring chemicals in cannabis have been shown to reduce cholesterol–and the risk of deadly fatty liver disease, ...

March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for ...

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, ...

The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...

Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to ...

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

CBD and CBG may help the liver recharge and clean itself—offering a promising new plant-based strategy against fatty liver disease.

A diagnosis of serious liver disease can feel like a slow countdown. Scar tissue builds quietly, the liver stiffens, and the ...

In experiments on pigs, researchers found that some formula fats can strain the newborn liver far earlier than expected.

Researchers have discovered that non-psychoactive cannabis compounds, CBD and CBG, can significantly reduce liver fat and ...

GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.